Temporospatial genomic profiling in glioblastoma
Tumor heterogeneity underlies resistance and disease progression in glioblastoma (GBM), and tumors most commonly recur adjacent to the surgical resection margins in contrast non-enhancing (NE) regions. To date no targeted therapies have meaningfully altered overall patient survival in the up-front setting. The aim of this study is to characterize intratumoral heterogeneity in recurrent GBM using bulk samples from primary resection and recurrent samples taken from contrast-enhancing (EN) and contrast non-enhancing (NE) regions.